BASEL (SWITZERLAND)
RC2NB Clinnova-MS
The Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), in collaboration with the University of Basel and University Hospital Basel, plays a leading role in the Switzerland arm of the Clinnova project. Specializing in the development of cutting-edge tools that deeply characterize neuroimmunological diseases, RC2NB is at the forefront of transforming the care and treatment of multiple sclerosis (MS). By focusing on personalized disease management and innovative treatment approaches, RC2NB is not just advancing science- it’s enhancing lives.
A Federated Network of Data Integration Centres
Clinnova-MS will enrol patients with beginning MS or patients in the transition phase to progressive MS. Up to 100 patients will be enrolled at the University Hospital Basel and a comparable number at the other Clinnova centres. As part of this, the Canton of Basel-Stadt provided CHF 4 million in funding for the Clinnova project.
Personal data and samples from study participants will be collected and analysed as well as data from follow-up visits over five years. “Patient Reported Outcomes” as well as cognitive and mobility measurements will be recorded using the smartphone application “dreaMS” which is currently being developed and validated at the RC2NB. Biological samples (blood, cerebrospinal fluid and stool) and imaging data will initially be stored locally and then transferred to the data centre in Luxembourg, the main centre responsible for the Clinnova project.
“The data we gather from our MS cohort, combined with AI-powered analysis, could reveal key characteristics linked to the early stages of MS and the critical transitions to progressive MS.”
Prof. Cristina Granziera
Partners
Leadership Team
Niess
